|Articles|September 22, 2016
EpiPen Controversy: Mylan CEO Faces Congressional Committee
Author(s)Pharmaceutical Technology
September 22, 2016
Advertisement
Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.
In her
For the rest of this news release, see
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain
2
CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo
3
FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant
4
Pharma Roundup: Mounjaro Shows Advantages in Type 2 Diabetes, Immune System Linked to Long Covid Symptoms
5